Results 181 to 190 of about 592,819 (238)

Lung‐Cardiovascular Interactions and Derangements in ARDS

Comprehensive Physiology, Volume 16, Issue 5, October 2026.
This review proposes an anatomical near‐ and far‐field framework for lung‐cardiovascular interactions in ARDS. Grounded in pathological and biological studies, the evidence spans pulmonary vascular, right ventricular, and systemic endothelial derangements and reviews available evidence for targeted therapies.
Pablo A. Sanchez, Connor O'Brien, Matthieu Legrand, Carolyn S. Calfee, Michael A. Matthay   +4 more
wiley   +1 more source

Macrophage lipid efflux regulates the tumour microenvironment in early‐stage lung adenocarcinoma

Clinical and Translational Discovery, Volume 6, Issue 5, October 2026.
1. Macrophages undergo metabolic rewiring even during early tumourigenesis. 2. Main alterations of macrophages are conserved between human and mice in early‐stage lung adenocarcinoma. 3. Tumour‐associated macrophages are characterised by enhanced lipid efflux 4.
Yujie Zheng, Yuan Wang, Yalin Wang, Yue Shi, Hui Kong, Shaohua Lu, Yong Zhang, Jie Hu, Jian Zhou, Xiangdong Wang, Meng Xiang, Qiong Liu, Hongyi Xin, Charles A. Powell, Fred R. Hirsch, Chunxue Bai, Yuanlin Song, Jun Yin, Dawei Yang   +18 more
wiley   +1 more source

Budesonide and Surfactant Therapy Versus Surfactant Alone on Incidence of Lung Disease in Preterm Infants (BEST Lung): Study Protocol for a Systematic Review and Individual Participant Data Meta‐Analysis With Nested Prospective Meta‐Analysis

Acta Paediatrica, Volume 115, Issue 10, Page 2078-2090, October 2026.
ABSTRACT Introduction Bronchopulmonary dysplasia (BPD) is a leading cause of morbidity and mortality in preterm infants. Combining surfactant with budesonide has been proposed to prevent BPD, but results from existing randomised controlled trials (RCTs) are conflicting.
James X. Sotiropoulos, Brett J. Manley, Sol Libesman, Namasivayam Ambalavanan, Abhik Das, Christopher J. D. Mckinlay, Nalinikanta Panigrahy, Melinda Cruz, David Nguyen, Jonathan Williams, Peter Davis, Kylie E. Hunter, Anna Lene Seidler   +12 more
wiley   +1 more source

Abstracts from the 2026 Congress of the Scandinavian Society of Anesthesiology and Intensive Care Medicine, Reykjavik, Iceland, June 10–12, 2026

Acta Anaesthesiologica Scandinavica, Volume 70, Issue 9, October 2026.
wiley   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Biomimetic pulmonary surfactants

Life Sciences, 1994
Considerable progress has been made in the development of defined mixtures of proteins or peptides with phospholipids which mimic the activity of natural pulmonary surfactants. Several of these biomimetic surfactants are active in animal models and clinical syndromes of surfactant deficiency.
Larry R McLean, L R McLean
exaly   +3 more sources

Pulmonary surfactant

Canadian Journal of Biochemistry and Cell Biology, 1984
The mammalian lung is stabilized by a specialized material, the pulmonary surfactant, which acts by reversibly reducing the surface tension at the air–liquid interface of the lung during breathing. Pulmonary surfactant contains approximately 90% lipid and 10% proteins. Dipalmitoyl phosphatidylcholine, the major lipid component, appears to be primarily
F, Possmayer, S H, Yu, J M, Weber, P G, Harding   +3 more
openaire   +2 more sources

The Pulmonary Surfactant System

Hospital Practice, 1990
Surfactant's importance is underscored by the severe morbidity of deficiency states--primary, as in neonatal respiratory distress syndrome, or secondary, as in ARDS. Current knowledge of surfactant synthesis and metabolism is reviewed. Clinically, the effectiveness of exogenous surfactant in RDS has prompted investigation of its administration in ARDS.
S P, Caminiti, S L, Young
openaire   +2 more sources

Pulmonary surfactant and tuberculosis

Tuberculosis, 2009
Mycobacterium tuberculosis comes in contact with pulmonary surfactant, alveolar macrophages and type II epithelial cells. Alveolar type II epithelial cells secrete pulmonary surfactant, a complex mixture of phospholipids and proteins lining the alveolar surface, while alveolar macrophages are involved in surfactant catabolism.
Zissis C, Chroneos, Krishna, Midde, Zvjezdana, Sever-Chroneos, Chinnaswamy, Jagannath   +3 more
openaire   +2 more sources

Pulmonary Surfactant Therapy

New England Journal of Medicine, 1993
In 1959, not long after surfactant had been identified as critical to maintaining lung inflation at low transpulmonary pressures,1,2 Avery and Mead3 reported that saline extracts from the lungs of preterm infants with respiratory distress syndrome lacked the low surface tension characteristic of pulmonary surfactant. After several unsuccessful attempts
Alastair J.J. Wood, Alan H. Jobe
openaire   +2 more sources

Pulmonary Surfactant Metabolism

Clinics in Chest Medicine, 1989
Recent work suggests that surfactant undergoes a complex sequence of metabolic events during its life cycle in the alveolar airspace. The composition, turnover, and metabolism of surfactant, and the possible "control points" in its metabolic pathway that might be compromised in disease states are discussed.
J R, Wright, S, Hawgood
openaire   +2 more sources